NASDAQ
8.13USD
-0.18 (-2.23%)
We have scored 5 news catalysts on Alpha Cognition Inc (ACOG) over the past 12 months. The biggest single-day move next to one of them came Jan 7, 2026, when ACOG closed +5.2%: “Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution”. Coverage across the window leans mixed (average ticker sentiment +0.06). Most of the impact sits in sector healthcare and earnings surprise volatility.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
125.8M
P/E
—
EPS
—
Beta
2.23
52W range
4.5-10.14
Day range
7.98–8.31
Open
8.30
Prev close
8.31
Volume
75.9K
Avg volume
110.3K
Dividend
0.00
IPO
2024-11-12
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Alpha Cognition Inc — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ACOG: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
